Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Clinical and Experimental Immunology

Volumn 116, Issue 2, 1999, Pages 206-213

  Roozendaal, C ^a   Kallenberg, C G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Anti neutrophil cytoplasmic antibodies; Crohn's disease; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; CELLULAR DISTRIBUTION; DIAGNOSTIC VALUE; ENTERITIS; GENETIC MARKER; PRIORITY JOURNAL; REVIEW;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIGENS, BACTERIAL; BIOLOGICAL MARKERS; CROSS REACTIONS; EPITOPES; HUMANS; INFLAMMATORY BOWEL DISEASES;

EID: 0032948263     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.00905.x     Document Type: Review

References (106)

1. 1 Van der Woude FJ, Lobatto S, Permin H et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; i:425-9.
2. 2 Niles JL, McCluskey RT, Ahmad MF, Arnaout MA. Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood 1989; 74:1888-93.
3. 3 Kallenberg CGM, Brouwer E, Weening JJ, Cohen Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiolical potential. Kidney Int 1994; 46:1-15.
4. 4 Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for mycloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318:1651-7.
5. 5 Charles LA, Falk RJ, Jennette JC. Reactivity of anti-neutrophil cytoplasmic autoantibodies with HL-60 cells. Clin Immunol Immunopathol 1989; 53:243-53.
6. 6 Kallenberg CGM, Mulder AHL, Cohen Tervaert JW. Antineutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. Am J Med 1992; 93:675-82.
7. 7 Saxon A, Shanahan F, Landers CJ et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990; 86:202-10.
8. 8 Rump JA, Schölmerich J, Gross V et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiol 1990; 181:406-13.
9. 9 Duerr RH, Targan SR, Landers CJ et al. Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterol 1991; 100:1385-91.
10. 10 Mulder AHL, Horst G, Haagsma EB et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatol 1993; 17:411-7.
11. 11 Roozendaal C, Van Milligen de Wit AWM, Haagsma EB et al. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am J Med 1998; 105:393-9.
12. 12 Lassoued S, Sixou L, Oksman F et al. Antineutrophil cytoplasmic antibodies and antibodies to myeloperoxidase in rheumatoid arthritis. Arthritis Rheum 1991; 34:1069-70.
13. 13 Mulder AML, Horst G, Van Leeuwen MA et al. Anti-neutrophil cytoplasmic antibodies in rheumatoid arthritis: characterization and clinical correlates. Arthritis Rheum 1993; 36:1054-60.
14. 14 Schnabel A, Csernok E, Isenberg DA et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus: prevalence, specificities, and clinical significance. Arthritis Rheum 1995; 38:633-7.
15. 15 Spronk PE, Bootsma H, Horst G et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Br J Rheumatol 1996; 35:625-31.
16. 16 Freeman HJ, Inflammatory bowel disease with cytoplasmic-staining antineutrophil cytoplasmic antibody and extensive colitis. Can J Gastroenterol 1998; 12:279-82.
17. 17 Fiocchi C, Inflammatory bowel disease: etiology and pathogenesis. Gastroenterol 1998; 115:182-205.
18. 18 Folwaezny C, Noehl N, Tsehop K et al. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterol 1997; 113:101-6.
19. 19 Geng X, Biancone L, Dai HH et al. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterol 1998; 114:912-22.
20. 20 Stevens TRJ, Harley SL, Groom et al. Anti-endothelial cell antibodies in inflammatory bowel disease. Dig Dis Sci 1993; 38:426-32.
21. 21 Klein R, Eisenburg J, Weber P et al. Significance and specificity of antibodies to neutrophils detected by Western blotting for the serological diagnosis of primary sclerosing cholangilis. Hepatol 1991; 14:1147-52.
22. 22 Duerr RH, Targan SR, Landers CJ et al. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis: comparison with other colitides/diarrheal illnesses. Gastroenterol 1991; 100:1590-6.
23. 23 Lo SK, Fleming KA, Chapman RWG. Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique. Gut 1992; 33:1370-5.
24. 24 Bansi DS, Chapman RW, Fleming KA. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1996; 8:881-5.
25. 25 Bansi DS, Bauducci M, Bergqvist A et al. Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: a comparison of the alkaline phosphatase and immunofluorescent techniques. Eur J Gastroenterol Hepatol 1997; 9:575-80.
26. 26 Peen E, Almer S, Bodemar G et al. Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Gut 1993; 34:56-62.
27. 27 Mulder AHL, Broekroelofs J, Horst G et al. Anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease: characterization and clinical correlates. Clin Exp Immunol 1994; 95:490-7.
28. 28 Stoffel MP, Csernok E, Herzberg C et al. Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol 1996; 104:54-59.
29. 29 Walmsley RS, Zhao MH, Hamilton ML et al. Anti-neutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease. Gut 1997; 40:105-9.
30. 30 Halbwachs-Mecarelli L, Nusbaum P, Noël LH et al. Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol 1992; 90:79-84.
31. 31 Mayet WJ, Hermann E, Finsterwalder J et al. Antibodies to cathepsin G in Crohn's disease. Eur J Clin Invest 1992; 22:427-33.
32. 32 Kossa K, Coulthart A, Ives CT et al. Antigen specificity of circulating anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7:783-9.
33. 33 Schmitt WH, Csernok E, Flesch BK et al. Autoantibodies directed against lysozyme: a new target antigen for anti-neutrophil cytoplasmic antibodies (ANCA). Adv Exp Med Biol 1993; 336:267-72.
34. 34 Nassberger L, Ljungh A, Schumacher G, Kollberg B. β-Glucoronidase antibodies in ulcerative colitis. Lancet 1992; 340:734-5.
35. 15 Kaneko K, Suzuki Y, Yamashiro Y, Yabuta K. Is p-ANCA in ulcerative colitis directed against β-glucuronidase? Lancet 1993; 341:320.
36. 36 Roozendaal C, Zhao MH, Horst G et al. Catalase and alpha-enolase: two novel granulocyte autoantigens in inflammatory bowel diseases. Clin Exp Immunol 1998; 112:10-6.
37. 37 Orth T, Kellner R, Diekmann O et al. Identification and characterization of autoantibodies against catalase and α-enolase in patients with primary sclerosing cholangitis. Clin Exp Immunol 1998; 112:507-15.
38. 38 Billing P, Tahir S, Calfin B et al. Nuclear localization of the antigen detected by ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies. Am J Pathol 1995; 147:979-87.
39. 39 Vidrich A, Lee J, James E et al. Segregation of pANCA antigenic recognition by DNase treatment of neutrophils: ulcerative colitis, type 1 autoimmune hepatitis, and primary sclerosing cholangitis. J Clin Immunol 1995; 15:293-9.
40. 40 Eggena M, Targan SR, Twanczyk L et al. Phage display cloning and characterization of an immunogenetic marker (perinuclear antineutrophil cytoplasmic antibody) in ulcerative colitis. J Immunol 1996; 156:4005-11.
41. 41 Eggena MP, Targan SR, Vidrich A et al. Histone H1: the UC-specific pANCA target antigen [abstract]. FASEB J 1996; 10:A1079.
42. 42 Cohavy O, Eggena MP, Parseghian M et al. Histone H1, a candidate pANCA antigen in ulcerative colitis [abstract], Gastroenterol 1997; 112:A951.
43. 43 Mizoguchi E, Mizoguchi A, Chiba C et al. Antineutrophil cytoplasmic antibodies in T-cell receptor α-deficient mice with chronic enterocolitis. Gastroenterol 1997; 113:1828-35.
44. 44 Sobajima J, Ozaki S, Osakada F et al. Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) in ulcerative colitis: non-histone chromosomal proteins, HMG1 and HMG2. Clin Exp Immunol 1997; 107:135-40.
45. 45 Terjung B, Herzog V, Worman HJ et al. Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatol 1998; 28:332-40.
46. 46 Stoffel MP, Csernok E, Gross WL. Target antigen for anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease, Scand J Gastroenterol 1996; 31:943-4.
47. 47 Schultz H, Csernok E, Johnston TW et al. Use of native and recombinant bactericidal/permeability-increasing proteins (BPI) as antigens for detection of BPI-ANCA. J Immunol Methods 1997; 205:127-33.
48. 48 Sobajima J, Ozaki S, Uesugi H et al. Prevalence and characterization of perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) directed against HMG1 and HMG2 in ulcerative colitis (UC). Clin Exp Immunol 1998; 111:402-7.
49. 49 Jones SJ, Zhao MH, Elliott JD, Lockwood CM. The antigenicity of bactericidal/permeability-increasing protein (BPI) is threatened by serine proteases [abstract]. Clin Exp Immunol 1995; 101 (Suppl. 1):36.
50. 50 Cohen Tervaert JW. The value of serial ANCA testing during follow-up studies in patients with ANCA-associated vasculitides: a review. J Nephrol 1996; 9:232-40.
51. 51 Shanahan F. Neutrophil autoantibodies in inflammatory bowel disease: are they important? Gastroenterol 1994; 107:586-9.
52. 52 Quinton JF, Sendid B, Reumaux D et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42:788-91.
53. 53 Targan SR, Landers CJ, Vidrich A, Czaja AJ. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterol 1995; 108:1159-66.
54. 54 Coremans IEM, Hagen EC, Daha MR et al. Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum 1992; 35:1466-75.
55. 55 Uesugi H, Ozaki S, Sobajima J et al. Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMGI and HMG2, in systemic rheumatic diseases. J Rheumatol 1998; 25:703-9.
56. 56 Sobajima J, Ozaki S, Okazaki T et al. Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlate with a refractory type. Clin Exp Immunol 1996; 105:120-4.
57. 57 Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996; 71:431-6.
58. 58 Reumaux D, Colombel JF, Duclos B et al. Antineutrophil cytoplasmic auto-antibodies in sera from patients with ucerative colitis after proctocolectomy with ileo-anal anastomosis. Adv Exp Med Biol 1993; 336:523-5.
59. 59 Patel RT, Stokes R, Birch D et al. Influence of total colectomy on serum antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Br J Surg 1994; 81:724-6.
60. 60 Yang P, Oresland T, Jarnerot G et al. Perinuclear antineutrophil cytoplasmic antibody in pouchitis after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. Scand J Gastroenterol 1996; 31:594-8.
61. 61 Aitola P, Miettinen A, Mattila M, Soppi E. Effect of proctocolectomy on serum antineutrophil cytoplasmic antibodies in patients with chronic ulcerative colitis. J Clin Pathol 1995; 48:645-7.
62. 62 Vecchi M, Gionchetti P, Bianchi MB et al. p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. Lancet 1994; 344:886-7.
63. 63 Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol 1995, 90:740-7.
64. 64 Esteve M, Mallolas J, Klaassen J et al. Antineutrophil cytoplasmic antibodies in sera from colectomised ulcerative colitis patients and its relation to the presence of pouchitis. Gut 1996; 38:894-8.
65. 65 Brett PM, Yasuda N, Yiannakou JY et al. Genetic and immunological markers in pouchitis, Eur J Gastroenterol Hepatol 1996; 8:951-5.
66. 66 Subramani K, Harpaz N, Bilotta J et al. Refractory pouchitis: does it reflect underlying Crohn's disease? Gut 1993; 34:1539-42.
67. 67 Aisenberg J, Wagreich J, Shim J et al. Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis: a case-control study. Dig Dis Sci 1995, 40:1866-72.
68. 68 Vasiliauskas EA, Plevy SE, Landers CJ et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterol 1996; 110:1810-9.
69. 69 Jamar-Leelerc N, Reumaux D, Duthilleul P, Colombel JF. Do pANCA define a clinical subgroup in patients with Crohn's disease? Gastroenterol 1997; 112:316-7.
70. 70 Oudkerk Pool M, Ellerbroek PM, Ridwan BU et al. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut 1993; 34:46-50.
71. 71 Schumacher G, Kollberg B, Sandstedt B et al. Circulating granulocyte antibodies in first attacks of colitis. Scand J Gastroenterol 1995; 30:157-63.
72. 72 Kerr GS, Fleisher TA, Hallahan CW et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36:365-71.
73. 73 Cohen Tervaert JW, Van der Woude FJ, Fauci AS et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Int Med 1989; 149:2461-5.
74. 74 Cohen Tervaert JW, Huitema MG, Hene RJ et al. Prevention of relapses of Wegener's granulomatosis by treatment based on anti-neutrophil cytoplasmic antibody titre. Lancet 1990; 336:709-11.
75. 75 Abad E, Tural C, Mirapeix E, Cuxart A. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity. J Autoimmun 1997; 10:175-80.
76. 76 Roozendaal C, Pogány K, Hummel EJ et al. Titers of anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease are not related to disease activity. Submitted for publication.
77. 77 Roozendaal C, Pogány K, Horst G et al. Does analysis of the antigenic specificities of anti-neutrophil cytoplasmic antibodies contribute to their clinical significance in the inflammatory bowel diseases? Submitted for publication.
78. 78 Shanahan F, Duerr RH, Rotter JI et al. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterol 1992; 103:456-61.
79. 79 Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterol 1994; 107:532-6.
80. 80 Reumaux D, Delecourt L, Colombel JF et al. Anti-neutrophil cytoplasmic autoantibodies in relatives of patients with ulcerative colitis. Gastroenterol 1992; 103:1706.
81. 81 Lee JCW, Lennard-Jones JE, Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterol 1995; 108:428-33.
82. 82 Papo M, Quer CJ, Pastor RM et al. Antineutrophil cytoplasmic antibodies in relatives of patients with inflammatory bowel disease. Am J Gastroenterol 1996; 91:1512-5.
83. 83 Bansi DS, Lo SK, Chapman RW, Fleming KA. Absence of anti-neutrophil cytoplasmic antibodies in relatives of UK patients with primary sclerosing cholangitis and ulcerative colitis. Eur J Gastroenterol Hepatol 1996; 8:111-6.
84. 84 Yang H, Rotter JI, Toyoda H et al. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and sub-clinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993; 92:1080-4.
85. 85 Mehal WZ, Lo SK, Chapman RW, Fleming KA. The immunogenetic basis for anti-neutrophil cytoplasmic antibody production in primary sclerosing cholangitis and ulcerative colitis. J Hepatol 1994; 21:910-1.
86. 86 Perri F, Annese V, Piepoli A et al. HLA antigens and pANCA define ulcerative colitis as a genetically heterogeneous disorder. Ital J Gastroenterol Hepatol 1998; 30:56-61.
87. 87 Satsangi J, Landers CJ, Welsh KI et al. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis 1998; 4:18-26.
88. 88 Yang H, Vora DK, Targan SR et al. Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease. Gastroenterol 1995; 109:440-8.
89. 89 Roussomoustakaki M, Satsangi J, Welsh K et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterol 1997; 112:1845-53.
90. 90 Falk RJ, Terrel RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87:4115-9.
91. 91 Mulder AHL, Heeringa P, Brouwer E et al. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies: a Fe RII-dependent process. Clin Exp Immunol 1994; 98:270-8.
92. 92 Van de Wiel BA, Dolman KM, Van der Meer-Gerritsen CH. Interference of Wegener's granulomatosis autoantibodies with neutrophil proteinase 3 activity. Clin Exp Immunol 1992; 90:409-14.
93. 93 Griffin SV, Lockwood CM. Anti-myeloperoxidase (MPO) antibodies interfere with the inhibition of MPO by caeruloplasmin [abstract]. The Immunologist 1997; 5 (Suppl. 1):94.
94. 94 Heeringa P, Brouwer E, Cohen Tervaert JW et al. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int 1998; 53:253-63.
95. 95 Gionchetti P, Vecchi M, Rizzello F et al. Lack of effect of anti-neutrophil cytoplasmic antibodies associated with ulcerative colitis on superoxide anion production from neutrophils. Gut 1997; 40:102-4.
96. 96 Peen E, Sundqvist T, Skogh T. Leucocyte activation by anti-lactoferrin antibodies bound to vascular endothelium. Clin Exp Immunol 1996; 103:403-7.
97. 97 Targan SR, Landers CJ, King NW et al. Ulcerative colitis-linked antineutrophil cytoplasmic antibody in the cotton-top tamarin model of colitis. Gastroenterol 1992; 102:1493-8.
98. 98 Magnuson JS, Henry JF, Yip TT, Hutchens TW. Structural homology of human, bovine, and porcine milk lactoferrins: evidence for shared antigenic determinants. Pediatr Res 1990; 28:176-81.
99. 99 Aguas AP, Esaguy N, Sunkel CE, Silva MT. Cross-reactivity and sequence homology between the 65-kilodalton mycobacterial heat shock protein and human lactoferrin, transferrin, and DRβ subsets of major histocompatibility complex class II molecules. Infect Immun 1990; 58:1461-70.
100. 100 Stevens TRJ, Winrow VR, Blake DR, Rampton DS. Circulating antibodies to heat-shock protein 60 in Crohn's disease and ulcerative colitis. Clin Exp Immunol 1992; 90:271-4.
101. 101 Spahn TW, Heimann H, Duchmann R et al. Cellular and humoral immunity to the 60-kD heat shock protein in inflammatory bowel disease. Digestion 1997; 58:469-75.
102. 102 Peen E, Eneström S, Skogh T. Distribution of lactoferrin and 60/65 kDa heat shock protein in normal and inflamed human intestine and liver. Gut 1996; 38:135-40.
103. 103 Cohavy O, Tayebali AB, Phu PK et al. Identification of candidate bacterial pathogens in ulcerative colitis using a disease-specific marker antibody [abstract]. Gastroenterol 1998; 114:G3906.
104. 104 Kühn R, Löhler J, Rennick D et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75:263-74.
105. 105 Seibold F, Brandwein S, Simpson S et al. pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol 1998; 18:153-60.
106. 106 Yang P, Danielsson D, Järnerot G. Escherichai coli and Proteus mirabilis inhibit the perinuclear but not the ciculating antineutrophil cytoplasmic antibody reaction. Scand J Gastroenterol 1998; 33:529-34.